Home > Products > CCR3 & CD300 > Recombinant Anti-CCR3 x Anti-CD300 Bispecific Antibody (scFv4-Ig)

Recombinant Anti-CCR3 x Anti-CD300 Bispecific Antibody (scFv4-Ig)  (FVTIG-028)

Recombinant Anti-CCR3 x Anti-CD300 Bispecific Antibody (scFv4-Ig) is an appended IgG format, which includes four scFv moieties at the N-termini of the constant regions. It is a bivalent homodimer, in which one anti-CCR3 scFv is fused to the CH1 domain of a heavy chain and another anti-CD300 scFv to the CL domain of a light chain, or vice versa. The resulting leads to 2+2 antigen-binding valency. This BsAb canreduce eosinophil signaling, inhibit bronchoalveolar lavage fluid inflammation, eosinophil, mast cell mediator release and reverse lung inflammation. It is designed for the research of Asthma therapy.

Specifications
Targets
CCR3 & CD300
Type
Appended IgGs
Species Reactivity
Human
Target 1
CCR3
Host Animal 1
Mouse
Target 2
CD300
Host Animal 2
Mouse
Application
FuncS; Promising therapeutic agent
Related Disease
Asthma
Targets
Target 1
CCR3
Gene ID
UniProt ID
Alternative Names
CCR3; C-C motif chemokine receptor 3; CKR3; CD193; CMKBR3; CC-CKR-3
Target 2
CD300
Gene ID
UniProt ID
Alternative Names
CD300A; CD300a molecule; IRC1; IRC2; CLM-8; IRp60; IGSF12; CMRF35H; CMRF-35H; CMRF35-H; CMRF35H9; CMRF35-H9; IRC1/IRC2; CMRF-35-H9
Our services and products are only for lab research, not for any diagnostic or therapeutic use.

Welcome! For price inquiries, we will get back to you as soon as possible.

To order, please email

INQUIRY
Online Inquiry
USA
45-1 Ramsey Road, Shirley, NY 11967, USA
Tel: 1-631-381-2994
Fax: 1-631-207-8356
Email:

Germany
Heidenkampsweg 58, 20097 Hamburg, Germany
Email:

UK
167-169 Great Portland Street, 5th Floor, London, W1W 5PE
Tel: 44-207-097-1828
Email:
Related products of "CCR3 & CD300"
24x7 CUSTOMER SERVICE
Easy access to products and services you need from our library via
powerful searching tools
© 2021 Creative-Biolabs All Rights Reserved.
Distributors
To view the contact information for a specific location,
select your country or region: